Eltrombopag/Revolade

Phase 2Small molecule

Eltrombopag/Revolade is one of 37 small molecule programs targeting Myelodysplastic Syndromes. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myelodysplastic SyndromesActive, not recruiting

Myelodysplastic SyndromesPhase 2

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Myelodysplastic Syndromes

#DrugCompanyPhaseTrials

Dacogen

Sun Pharmaceutical Industries, Inc.

Approved

18 2

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

38 3

Cytosar

Teva

Approved

13 4

Idamycin

Pfizer

Approved

6 5

Reblozyl

Bristol-Myers Squibb

Phase 3

15 6

Evrenzo

Astellas

Phase 3

2 7

Xospata

Astellas

Phase 3

1 8

Rytelo

Fludara

5 10

Arava

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myelodysplastic Syndromes1 trial

Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes

Active, not recruiting·AAssociazione Qol-one·Phase 2·NCT02912208·174 enrolled

Myelodysplastic Syndrome1 trial

Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q

Terminated·AAssociazione Qol-one·Phase 2·NCT02928419·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Eltrombopag/Revolade. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Eltrombopag/Revolade compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Eltrombopag/Revolade. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Associazione Qol-one company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAssociazione Qol-one

Eltrombopag/Revolade

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myelodysplastic Syndromes1 trial

Myelodysplastic Syndrome1 trial

References

Drug Info

Quick Facts

Related News